The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grimaldi, L. M.
Right arrow Articles by Lazzarin, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grimaldi, L. M.
Right arrow Articles by Lazzarin, D.

The Journal of Immunology, Vol 141, Issue 1 114-117, Copyright © 1988 by American Association of Immunologists

ARTICLES

Restricted heterogeneity of antibody to gp120 and p24 in AIDS

LM Grimaldi, RP Roos, SG Devare, WG Robey, JM Casey, ME Gurney, BR Apatoff and D Lazzarin
Abbott Laboratories, North Chicago, IL 60064.

Neurologic complications and cerebrospinal fluid (CSF) abnormalities are common in AIDS. We found that a substantial number of AIDS patients with neurologic involvement had oligoclonal IgG bands in CSF and sera by IEF. Using an IEF-Ag overlay technique, anti-gp120 antibody activity was demonstrated more frequently than anti-p24 antibody activity. These antibody activities exhibited restricted heterogeneity of their IEF pattern; this restriction may contribute to the relatively low titers of neutralizing antibody found in AIDS sera. None of the CSF and serum oligoclonal bands showed anti-HIV antibody activity, suggesting that they are directed against opportunistic agents or result from immunodysregulation.


This article has been cited by other articles:


Home page
 J. Virol.Home page
P. Seiler, B. M. Senn, P. Klenerman, U. Kalinke, H. Hengartner, and R. M. Zinkernagel
Additive Effect of Neutralizing Antibody and Antiviral Drug Treatment in Preventing Virus Escape and Persistence
J. Virol., July 1, 2000; 74(13): 5896 - 5901.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
P. Seiler, B. M. Senn, M.-A. Brundler, R. M. Zinkernagel, H. Hengartner, and U. Kalinke
In Vivo Selection of Neutralization-Resistant Virus Variants But No Evidence of B Cell Tolerance in Lymphocytic Choriomeningitis Virus Carrier Mice Expressing a Transgenic Virus-Neutralizing Antibody
J. Immunol., April 15, 1999; 162(8): 4536 - 4541.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Konrad, L. J. Kricka, D. Goodman, J. Goldman, and L. Silberstein
Myeloma-Associated Paraprotein Directed against the HIV-1 p24 Antigen in an HIV-1-Seropositive Patient
N. Engl. J. Med., June 24, 1993; 328(25): 1817 - 1819.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.